Lallemand inaugurates new research and development laboratories
Blagnac, France, September 4, 2024 – Lallemand proudly announces the inauguration of its new laboratories in France, increasing its capacity by over 800 square meters. This significant expansion enhances its interdisciplinary research and development capabilities at the Blagnac and Beauzelle sites. The investment of over 1.7 million euros will enable the seventy scientists and technicians working at these two sites to continue their involvement in ambitious research and development programs.
This expansion, coupled with the acquisition of new, state-of-the-art equipment, will enable Lallemand to strengthen its bioprocess innovation cluster and accelerate the development of next-generation strains. The research departments of the following business units: Specialty Cultures, Oenology, Animal Health, Human Health, and Plant Care, will benefit from these new spaces and technologies, expanding the possibilities offered by the microorganisms they are studying.
Sylvie Binda, Vice-President of Research and Development at Lallemand Health Solutions, stated: “Strengthening our fermentation process capabilities is a strategic priority for Lallemand. This commitment is reflected in the creation of laboratories of excellence, the training of teams, and the implementation of collaborative research programs aimed at leveraging complementary expertise to optimize the impact of our initiatives.”
Patrice Pellerin, Vice-President of Quality and Production Technology at Lallemand Plant Care, confirms: “These new facilities will enable us to accelerate the development of products based on living microorganisms—bacteria or filamentous fungi—that will be used in plant production as biocontrols or biofertilizers.”
Antoine Chagnon, CEO of Lallemand, declares: “At Lallemand, we firmly believe that microbial solutions can help us meet the challenges of today and tomorrow. To realize this potential, we reinvest 3 to 5% of our sales in research and development every year to support our teams of over 400 researchers in a dozen centers around the world. The expansion of our laboratories in the Toulouse region is part of this ongoing drive to extend our capabilities both internally and with external collaborators. We are proud to celebrate this important milestone with them today.”
Lallemand invited numerous partners, political representatives, scientists, and media to celebrate this important milestone and to explore its new, operational premises during the inauguration day on September 4, 2024, at its site in the Toulouse region.
Lallemand is a world leader in the development, production, and marketing of yeasts, bacteria, fungi, and their derivatives. The company has a microorganism bank that includes thousands of proprietary strains. With the aim of managing and optimizing fermentation processes, Lallemand offers its customers the precise microorganisms or derivatives that meet their unique needs, as well as the support, knowledge, and expertise that come from more than 160 years of continuous production, research, and development in this field. Lallemand’s international presence includes a global network of 49 yeast and bacteria, fungi, and specialty product plants, as well as research and development facilities, distribution centers, and sales offices in more than 50 countries on five continents, with more than 5,000 employees spread throughout its network.
Media contact
Marilou Luneau, Communications Manager, Lallemand Health Solutions
mluneau@lallemand.com
